biostudies-literatureUnknown94(1128)Miller REAdvanced ovarian and endometrial cancers have historically been associated with poor prognosis and few treatment options, limited to single or doublet chemotherapy regimens. The introduction of novel target therapies has transformed the management of these cancers. In contrast to chemotherapy, which inhibits DNA replication and mitosis, targeted therapies target cancer signalling pathways, stroma, immune-microenvironment and vasculature in tumour tissues. The most notable advances in gynaecological cancers have come from the introduction of PARP inhibitors and immune checkpoint inhibitors for ovarian and endometrial cancer, respectively. Several PARP inhibitors, which target defective DNA repair, have been approved as maintenance therapy for advanced ovarian cancer in both the first line aThe British journal of radiology20210002https://www.ebi.ac.uk/biostudies/studies/S-EPMC8631040biostudies-literaturePARP inhibitors and immunotherapy in ovarian and endometrial cancers.PMC8631040Miller RELewis AJPowell MEfalsePARP inhibitors and immunotherapy in ovarian and endometrial cancers.Advanced ovarian and endometrial cancers have historically been associated with poor prognosis and few treatment options, limited to single or doublet chemotherapy regimens. The introduction of novel target therapies has transformed the management of these cancers. In contrast to chemotherapy, which inhibits DNA replication and mitosis, targeted therapies target cancer signalling pathways, stroma, immune-microenvironment and vasculature in tumour tissues. The most notable advances in gynaecological cancers have come from the introduction of PARP inhibitors and immune checkpoint inhibitors for ovarian and endometrial cancer, respectively. Several PARP inhibitors, which target defective DNA repair, have been approved as maintenance therapy for advanced ovarian cancer in both the first line a2021-01-01T00:00:00Z2021 Dec2025-04-04T22:33:44.438Z2025-02-19T03:23:59.771ZS-EPMC86310403388224110.1259/bjr.20210002